RHC – UBS rates the stock as Neutral

UBS has quantified the volume of non-urgent elective surgery that was likely deferred across Australia during the peak of the pandemic-related restrictions.

Analysis indicates that to clear the backlog the company would need to run at 118% capacity utilisation until the end of 2020.

However, there are obvious limitations such as access to nurses, adequate PPE and future outbreaks of coronavirus.

UBS does not expect a utilisation rate above 100% of previous levels will be achieved in the first half of FY21.

Still, the outlook for private hospital operator volumes is favourable. Neutral rating retained. Target is $71.20.

Sector: Health Care Equipment & Services.

Target price is $71.20.Current Price is $65.66. Difference: $5.54 – (brackets indicate current price is over target). If RHC meets the UBS target it will return approximately 8% (excluding dividends, fees and charges – negative figures indicate an expected loss).

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →